Dhanir Tailor
YOU?
Author Swipe
View article: Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer
Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer Open
Cancer cells exploit and overexpress glycolytic enzymes such as enolase 1 (ENO1) to sustain the Warburg effect, a hallmark of cancer metabolism, which makes ENO1 a compelling therapeutic target. Here, we demonstrate that SU212, a small mol…
View article: Novel Aza-podophyllotoxin Derivative Inhibits Growth of Triple-Negative Breast Cancer
Novel Aza-podophyllotoxin Derivative Inhibits Growth of Triple-Negative Breast Cancer Open
Triple-negative breast cancer (TNBC), the most aggressive type of breast cancer, has high rates of metastasis and recurrence and represents 15-20% of diagnosed breast cancer cases. Most women with TNBC experience recurrence following curat…
View article: Designing Cyclic Nitrogen‐Bridged Sulfonamides with Anti‐Cancer Activity
Designing Cyclic Nitrogen‐Bridged Sulfonamides with Anti‐Cancer Activity Open
The N‐bridgehead heterocyclic structure is an abundant motif in a multitude of natural products. This structural feature is of high interest because it is present in many different bioactive molecules, many of which are well‐established ph…
View article: Mycobacterium w - a promising immunotherapeutic intervention for diseases
Mycobacterium w - a promising immunotherapeutic intervention for diseases Open
Immunomodulating agents interact with the immune system and alter the outcome of specific immune processes. As our understanding of the immune system continues to evolve, there is a growing effort to identify agents with immunomodulating a…
View article: Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization
Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization Open
View article: MDB-104. TARGETING Y BOX BINDING PROTEIN (YBX1) IN PEDIATRIC MEDULLOBLASTOMA
MDB-104. TARGETING Y BOX BINDING PROTEIN (YBX1) IN PEDIATRIC MEDULLOBLASTOMA Open
Medulloblastoma is the most common malignant pediatric brain tumor, with some patients having abysmal survival despite an intense therapeutic regimen. A significant barrier to effective outcomes is cell-intrinsic resistance to chemo- and r…
View article: Clonal spheroids capture functional and genetic heterogeneity of head and neck cancer
Clonal spheroids capture functional and genetic heterogeneity of head and neck cancer Open
Head and neck cancer squamous cell carcinoma (HNSCC) cells exhibit both structural and functional diversity, making them valuable models for understanding tumor heterogeneity at clinical levels. In this study, we generated single-cell-deri…
View article: Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy
Inhibition of protein translational machinery in triple-negative breast cancer as a promising therapeutic strategy Open
Y-box binding protein-1 (YB-1) is a proto-oncogenic protein associated with protein translation regulation. It plays a crucial role in the development and progression of triple-negative breast cancer (TNBC). In this study, we describe a pr…
View article: EXTH-32. SYNERGISTIC EFFICACY OF Y BOX BINDING PROTEIN 1 (YBX1) INHIBITION COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF <i>MYC</i>-AMPLIFIED MEDULLOBLASTOMA
EXTH-32. SYNERGISTIC EFFICACY OF Y BOX BINDING PROTEIN 1 (YBX1) INHIBITION COMBINED WITH CHEMOTHERAPY FOR THE TREATMENT OF <i>MYC</i>-AMPLIFIED MEDULLOBLASTOMA Open
Medulloblastoma is the most common pediatric brain tumor in children. Patients diagnosed with MYC-amplified group 3 (G3) have a dismal prognosis with a 5 year survival rate of < 50%. Standard of care consists of maximal resection surger…
View article: Guanylate-binding protein 1 modulates proteasomal machinery in ovarian cancer
Guanylate-binding protein 1 modulates proteasomal machinery in ovarian cancer Open
Guanylate-binding protein 1 (GBP1) is known as an interferon-γ-induced GTPase. Here, we used genetically modified ovarian cancer (OC) cells to study the role of GBP1. The data generated show that GBP1 inhibition constrains the clonogenic p…
View article: Synthesis of potent antileukemic quinazoline-thiohydantoin fused heterocycles enabled by metal-free domino reaction
Synthesis of potent antileukemic quinazoline-thiohydantoin fused heterocycles enabled by metal-free domino reaction Open
Heterocyclic compounds play a central role in drug development research and are contained in most pharmaceuticals on the market. Quinazoline and thiohydantoin are heterocycles and hold very prominent positions due to their diverse pharmaco…
View article: Supplementary Figure Legend from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Supplementary Figure Legend from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
PDF - 68K, Figure legend for Supplementary Figure 1.
View article: Data from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Data from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
Angiogenesis is an effective target in cancer control. The antiangiogenic efficacy and associated mechanisms of acacetin, a plant flavone, are poorly known. In the present study, acacetin inhibited growth and survival (up to 92%; P …
View article: Supplementary Figure Legend from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Supplementary Figure Legend from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
PDF - 68K, Figure legend for Supplementary Figure 1.
View article: Data from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Data from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
Angiogenesis is an effective target in cancer control. The antiangiogenic efficacy and associated mechanisms of acacetin, a plant flavone, are poorly known. In the present study, acacetin inhibited growth and survival (up to 92%; P …
View article: Supplementary Figure 1 from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Supplementary Figure 1 from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
PDF - 161K, Effect of acacetin on TCM-stimulated capillary tube formation by HUVEC on matrigel.
View article: Supplementary Figure 1 from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression
Supplementary Figure 1 from Acacetin Inhibits <i>In Vitro</i> and <i>In Vivo</i> Angiogenesis and Downregulates Stat Signaling and VEGF Expression Open
PDF - 161K, Effect of acacetin on TCM-stimulated capillary tube formation by HUVEC on matrigel.
View article: Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed…
View article: Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
View article: Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Supplementary Figure from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
View article: Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
View article: Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Data from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed…
View article: Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Supplementary Table from Reengineering Ponatinib to Minimize Cardiovascular Toxicity
View article: Augmenting Vaccine Efficacy against Delta Variant with ‘Mycobacterium-w’-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways
Augmenting Vaccine Efficacy against Delta Variant with ‘Mycobacterium-w’-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways Open
Mycobacterium-w (Mw) was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in September 2020 …
View article: Augmenting vaccine efficacy against delta variant with ‘Mycobacterium-<i>w</i>’ mediated modulation of NK-ADCC and TLR-MYD88 pathways
Augmenting vaccine efficacy against delta variant with ‘Mycobacterium-<i>w</i>’ mediated modulation of NK-ADCC and TLR-MYD88 pathways Open
SUMMARY Mycobacterium-w (Mw), was shown to boost adaptive natural killer (ANK) cells and protect against COVID-19 during the first wave of the pandemic. As a follow-up of the trial, 50 healthcare workers (HCW) who had received Mw in Septem…
View article: 2022-RA-1711-ESGO Ovarian epithelial cell population as a novel cell and therapeutic tool for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)
2022-RA-1711-ESGO Ovarian epithelial cell population as a novel cell and therapeutic tool for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) Open
View article: Reengineering Ponatinib to Minimize Cardiovascular Toxicity
Reengineering Ponatinib to Minimize Cardiovascular Toxicity Open
Small molecule tyrosine kinase inhibitors (TKI) have revolutionized cancer treatment and greatly improved patient survival. However, life-threatening cardiotoxicity of many TKIs has become a major concern. Ponatinib (ICLUSIG) was developed…
View article: Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19
Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19 Open
The kinetics of NKG2C + adaptive natural killer (ANK) cells and NKG2A + inhibitory NK (iNK) cells with respect to the incidence of SARS-CoV-2 infection were studied for 6 months in a cohort of healthcare workers following the administratio…
View article: Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide‐Based Hybrid Compounds against SARS‐CoV‐2 and Cancer
Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide‐Based Hybrid Compounds against SARS‐CoV‐2 and Cancer Open
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) cause life‐threatening diseases in millions of people worldwide, in particular, in patients with cancer, and there is an urgent need for antiviral agents agains…
View article: SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer
SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer Open
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe a small molecule, SU086, as a therapeutic strategy for advanced prostate cancer.…